Does Gateway Health Plan Cover Forteo?

Understanding Gateway Health Plan's Formulary Structure

Gateway Health Plan operates as a Medicaid managed care organization primarily serving members in Pennsylvania. Its formulary, the list of covered medications, follows a tiered structure that places specialty medications like Forteo in higher cost-sharing categories. Forteo is classified as a specialty injectable, which means it sits on a non-preferred or specialty tier in most Gateway formulary editions.

Coverage decisions for Forteo align with clinical guidelines from the American Association of Clinical Endocrinology (AACE) and the Endocrine Society. These organizations recommend anabolic agents like teriparatide for patients at very high fracture risk, defined as those with a T-score of -2.5 or lower with a prior fragility fracture, those with multiple vertebral fractures, or those with a T-score below -3.0 even without fracture history [1]. Gateway Health Plan uses these clinical benchmarks when adjudicating prior authorization requests.

Because Gateway primarily administers Medicaid benefits, many members may pay reduced or zero copays depending on income eligibility. Pennsylvania Medicaid rules cap monthly copayments for prescription drugs, which can significantly reduce out-of-pocket exposure for Forteo compared to commercial insurance plans [2].

Prior Authorization Requirements for Forteo

Gateway Health Plan requires prior authorization before dispensing Forteo. This is standard practice across nearly all managed care plans for anabolic osteoporosis agents. The prior authorization process serves as a clinical checkpoint to verify that the medication is appropriate for the patient.

To obtain approval, the prescribing physician must typically submit documentation of the following: a confirmed diagnosis of osteoporosis via DXA scan with a T-score at or below -2.5, evidence that the patient has tried and either failed or cannot tolerate at least one oral bisphosphonate (such as alendronate or risedronate), and a clinical rationale explaining why Forteo is medically necessary. For patients with glucocorticoid-induced osteoporosis, the threshold may differ. The American College of Rheumatology 2022 guidelines recommend anabolic therapy as initial treatment for adults age 40 and older on glucocorticoids who have very high fracture risk, bypassing the bisphosphonate step in some cases [3].

The prior authorization form is generally available through the Gateway Health Plan provider portal. Turnaround time for standard reviews is typically 5 to 10 business days, though urgent requests can be processed within 24 to 72 hours. Denials include written explanation and instructions for appeal.

Step Therapy: What You Must Try First

Step therapy is the single biggest barrier between a Forteo prescription and an approved claim. Gateway Health Plan, like most Medicaid managed care organizations, requires that patients demonstrate an adequate trial of less costly first-line agents before approving a specialty medication.

For osteoporosis, first-line agents include oral bisphosphonates. Alendronate (Fosamax), the most widely prescribed, reduced hip fracture risk by 53% in the Fracture Intervention Trial (FIT; N=2,027) among women with existing vertebral fractures [4]. Risedronate and ibandronate are other options in this class. An adequate trial typically means at least 12 months of therapy with documented adherence, followed by evidence of treatment failure. Treatment failure can include a new fragility fracture while on therapy, continued bone mineral density (BMD) decline of 5% or more on serial DXA, or documented intolerance (such as esophageal irritation or GI side effects that prevent continued use).

Denosumab (Prolia) may also be considered a step-therapy option before Forteo, depending on the specific Gateway formulary edition. Some plans require failure of both a bisphosphonate and denosumab before approving an anabolic agent. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced vertebral fracture risk by 68% and hip fracture risk by 40% over 36 months compared to placebo [5].

If your physician believes that starting directly with Forteo is clinically warranted (for example, in cases of multiple vertebral fractures or a T-score below -3.5), a step-therapy exception request can be submitted. This is a separate process from standard prior authorization and requires detailed clinical justification.

What Forteo Costs Under Gateway Health Plan

The retail price of Forteo without insurance runs approximately $4,100 for a single 28-day injection pen. That figure rarely reflects what a Gateway Health Plan member actually pays.

For Medicaid-eligible members, Pennsylvania law limits prescription copayments. Most Medicaid beneficiaries pay between $1 and $3 per prescription, regardless of the drug's wholesale cost. This makes Forteo dramatically more affordable under Medicaid managed care than under many commercial plans, where specialty tier copays can reach 25% to 33% of the drug cost [6].

For members enrolled in Gateway's Medicare Advantage plans (where applicable), cost-sharing may follow a different structure. Specialty tier drugs under Medicare Part D typically carry coinsurance of 25% to 33% after the deductible, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) now limits total yearly drug spending for Medicare beneficiaries. This cap can make Forteo significantly more manageable financially than it was before 2025.

The availability of teriparatide biosimilars has also begun to affect pricing. The FDA approved teriparatide-rwbb in 2023, and biosimilar competition could reduce plan acquisition costs by 15% to 30% based on historical biosimilar pricing patterns observed with other biologic medications [7]. If Gateway Health Plan adds a biosimilar teriparatide to its preferred formulary, members may face lower cost-sharing or fewer prior authorization hurdles by opting for the biosimilar version.

Forteo's Clinical Evidence: Why Plans Cover It

Forteo earned FDA approval based on a body of evidence showing that teriparatide is the only widely available anabolic agent that builds new bone rather than simply slowing bone loss. The key Neer et al. trial (N=1,637) published in the New England Journal of Medicine demonstrated that teriparatide 20 mcg daily reduced new vertebral fractures by 65% and nonvertebral fractures by 53% compared to placebo over a median of 19 months [8].

That trial established the 24-month treatment duration that remains the FDA-labeled maximum. The 24-month limit exists because preclinical studies in rats showed an increased incidence of osteosarcoma with long-duration, high-dose teriparatide exposure, although post-marketing surveillance in humans over 15 years has not confirmed this risk in clinical practice [9].

More recent data from the VERO trial (N=680) directly compared teriparatide to risedronate in postmenopausal women with severe osteoporosis. The results were striking. Teriparatide reduced new vertebral fractures by 56% relative to risedronate over 24 months, and clinical fractures (including nonvertebral) were 52% lower in the teriparatide group [10]. Dr. Benjamin Leder, an endocrinologist at Massachusetts General Hospital, has noted: "The VERO data changed our approach. For patients with severe osteoporosis and existing fractures, starting with an anabolic agent rather than an antiresorptive produces better skeletal outcomes."

The Endocrine Society's 2019 clinical practice guideline recommends teriparatide as initial therapy for postmenopausal women at very high fracture risk, stating: "In postmenopausal women with osteoporosis at very high risk of fracture, such as those with severe or multiple vertebral fractures, we suggest initial treatment with bone-forming therapy over antiresorptive therapy" [11].

How to Appeal a Denial

Denials happen. If Gateway Health Plan denies prior authorization for Forteo, the member and prescribing physician have the right to appeal. Pennsylvania Medicaid regulations require that managed care organizations provide at least two levels of internal appeal before external review becomes available.

The first step after receiving a denial letter is to review the stated reason. Common denial reasons include insufficient documentation of bisphosphonate failure, missing DXA scan results, or incomplete clinical notes. In many cases, a denial can be overturned simply by resubmitting with the missing documentation attached.

For the formal appeal, the prescribing physician should submit a letter of medical necessity that addresses the specific denial reason, includes all relevant DXA results and fracture history, references clinical guidelines supporting Forteo use for the patient's specific situation, and provides documentation of prior treatment attempts. The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) treatment algorithm can serve as supporting evidence in appeal letters [12].

If the internal appeal is denied, Pennsylvania Medicaid members can request a fair hearing through the state Department of Human Services. Medicare Advantage members enrolled in Gateway plans may request an independent review entity (IRE) determination. These external reviews are binding on the plan if decided in the member's favor.

Alternatives if Forteo Is Not Covered

If Forteo coverage proves unattainable through Gateway Health Plan, several alternatives exist for osteoporosis treatment. Each carries its own coverage profile.

Teriparatide biosimilar. If Gateway's formulary prefers the biosimilar version of teriparatide, switching to teriparatide-rwbb may resolve coverage issues while delivering the same active molecule and clinical effect.

Abaloparatide (Tymlos). This is another parathyroid hormone analog approved for postmenopausal osteoporosis. The ACTIVE trial (N=2,463) showed that abaloparatide reduced new vertebral fractures by 86% versus placebo over 18 months [13]. Gateway Health Plan may have different prior authorization criteria for Tymlos compared to Forteo.

Romosozumab (Evenity). A sclerostin inhibitor with both bone-building and antiresorptive properties. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone over 24 months [14]. Romosozumab carries a cardiovascular warning and is contraindicated in patients with recent myocardial infarction or stroke.

Denosumab (Prolia). An antiresorptive biologic administered as a subcutaneous injection every six months. While it does not build new bone the way Forteo does, it is often covered with fewer prior authorization barriers and may be appropriate for patients at high (but not very high) fracture risk.

Oral bisphosphonates. Alendronate and risedronate remain the most cost-effective options with the broadest formulary coverage. Generic alendronate costs as little as $4 to $10 per month. For patients who have not yet tried bisphosphonate therapy, starting here is both clinically appropriate and the fastest path to treatment initiation.

Manufacturer Assistance and Patient Support

Eli Lilly, the manufacturer of Forteo, operates the Lilly Cares Foundation Patient Assistance Program for eligible patients who cannot afford their medication. Eligibility is based on income (typically at or below 400% of the federal poverty level), lack of prescription coverage for the specific medication, and U.S. residency. Patients enrolled in Medicaid are generally not eligible for manufacturer assistance programs due to federal anti-kickback regulations, but patients in Medicare Part D coverage gaps or those with commercial insurance may qualify.

The Forteo Savings Card program (for commercially insured patients) can reduce copays to as little as $4 per month, though this benefit does not apply to government-funded insurance including Medicaid and Medicare. Members of Gateway Health Plan should verify their specific plan type before applying, as eligibility depends on whether coverage falls under Medicaid, Medicare Advantage, or a commercial product.

The Bone Health & Osteoporosis Foundation also maintains a list of patient assistance resources and can help connect patients with state pharmaceutical assistance programs that may supplement their Gateway Health Plan coverage [12].

Timing Matters: When to Start and What Comes After

The sequence of osteoporosis therapy matters as much as the individual drug choice. Research published in the Journal of Bone and Mineral Research has shown that starting with an anabolic agent (like Forteo) and then transitioning to an antiresorptive (like denosumab or a bisphosphonate) produces greater BMD gains than the reverse sequence [15]. This "anabolic-first" strategy gained strong support from the DATA-Switch extension study, which found that women who received teriparatide first followed by denosumab achieved spine BMD increases of 18.3% over 4 years, compared to 14.0% for those who started with denosumab and then switched to teriparatide.

This sequencing evidence is relevant to Gateway Health Plan coverage discussions because it argues against prolonged bisphosphonate use before anabolic therapy in patients who clearly qualify for Forteo. A well-documented prior authorization request can reference this evidence to support earlier access to teriparatide for patients at very high fracture risk.

After completing the 24-month Forteo course, patients must transition to an antiresorptive agent to maintain the bone density gains achieved during treatment. Stopping Forteo without follow-on therapy leads to rapid BMD loss. The Endocrine Society guideline recommends transitioning to either denosumab or a bisphosphonate immediately after completing anabolic therapy [11]. Gateway Health Plan typically covers these follow-on therapies under standard formulary terms with fewer prior authorization requirements than the initial Forteo approval.